Display options
Cite
Miyanohara A, Kamizato K, Juhas S, et al. Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Mol Ther Methods Clin Dev. 2016;3:16046doi: 10.1038/mtm.2016.46.
Miyanohara, A., Kamizato, K., Juhas, S., Juhasova, J., Navarro, M., Marsala, S., Lukacova, N., Hruska-Plochan, M., Curtis, E., Gabel, B., Ciacci, J., Ahrens, E. T., Kaspar, B. K., Cleveland, D., & Marsala, M. (2016). Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Molecular therapy. Methods & clinical development, 316046. https://doi.org/10.1038/mtm.2016.46
Miyanohara, Atsushi, et al. "Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs." Molecular therapy. Methods & clinical development vol. 3 (2016): 16046. doi: https://doi.org/10.1038/mtm.2016.46
Miyanohara A, Kamizato K, Juhas S, Juhasova J, Navarro M, Marsala S, Lukacova N, Hruska-Plochan M, Curtis E, Gabel B, Ciacci J, Ahrens ET, Kaspar BK, Cleveland D, Marsala M. Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Mol Ther Methods Clin Dev. 2016 Jul 13;3:16046. doi: 10.1038/mtm.2016.46. eCollection 2016. PMID: 27462649; PMCID: PMC4943453.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Methods Clin Dev. 2016 Jul 13;3:16046. doi: 10.1038/mtm.2016.46. eCollection 2016.

Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs.

Molecular therapy. Methods & clinical development

Atsushi Miyanohara, Kota Kamizato, Stefan Juhas, Jana Juhasova, Michael Navarro, Silvia Marsala, Nada Lukacova, Marian Hruska-Plochan, Erik Curtis, Brandon Gabel, Joseph Ciacci, Eric T Ahrens, Brian K Kaspar, Don Cleveland, Martin Marsala

Affiliations

  1. Neuroregeneration Laboratory, Department of Anesthesiology, University of California , San Diego, California, USA.
  2. Institute of Animal Physiology and Genetics, Czech Academy of Sciences , Libechov, Czech Republic.
  3. Institute of Neurobiology, Slovak Academy of Sciences , Kosice, Slovak Republic.
  4. Institute of Molecular Life Sciences, University of Zurich , Zurich, Switzerland.
  5. Department of Neurosurgery, University of California , San Diego, California, USA.
  6. Department of Radiology, University of California , San Diego, California, USA.
  7. Department of Pediatrics, The Ohio State University, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
  8. Ludwig Institute and Department of Cellular and Molecular Medicine, University of California, San Diego, California, USA; Ludwig Institute and Department of Neurosciences, University of California, San Diego, California, USA.
  9. Neuroregeneration Laboratory, Department of Anesthesiology, University of California, San Diego, California, USA; Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic.

PMID: 27462649 PMCID: PMC4943453 DOI: 10.1038/mtm.2016.46

Abstract

Effective in vivo use of adeno-associated virus (AAV)-based vectors to achieve gene-specific silencing or upregulation in the central nervous system has been limited by the inability to provide more than limited deep parenchymal expression in adult animals using delivery routes with the most clinical relevance (intravenous or intrathecal). Here, we demonstrate that the spinal pia membrane represents the primary barrier limiting effective AAV9 penetration into the spinal parenchyma after intrathecal AAV9 delivery. We develop a novel subpial AAV9 delivery technique and AAV9-dextran formulation. We use these in adult rats and pigs to show (i) potent spinal parenchymal transgene expression in white and gray matter including neurons, glial and endothelial cells after single bolus subpial AAV9 delivery; (ii) delivery to almost all apparent descending motor axons throughout the length of the spinal cord after cervical or thoracic subpial AAV9 injection; (iii) potent retrograde transgene expression in brain motor centers (motor cortex and brain stem); and (iv) the relative safety of this approach by defining normal neurological function for up to 6 months after AAV9 delivery. Thus, subpial delivery of AAV9 enables gene-based therapies with a wide range of potential experimental and clinical utilizations in adult animals and human patients.

References

  1. Exp Neurol. 2004 Nov;190(1):122-32 - PubMed
  2. Mol Ther. 2015 Mar;23(3):477-87 - PubMed
  3. Mol Ther. 2013 Dec;21(12 ):2148-59 - PubMed
  4. Science. 1976 Jun 25;192(4246):1357-8 - PubMed
  5. J Neurotrauma. 2012 Feb 10;29(3):499-513 - PubMed
  6. J Virol. 1998 Mar;72(3):2224-32 - PubMed
  7. Mol Ther. 2014 Feb;22(2):329-37 - PubMed
  8. Acta Neuropathol. 1993;86(1):55-64 - PubMed
  9. Mol Ther. 2009 Jul;17(7):1187-96 - PubMed
  10. J Neurotrauma. 1995 Feb;12(1):1-21 - PubMed
  11. Cell Transplant. 2010;19(9):1103-22 - PubMed
  12. Hum Gene Ther Methods. 2015 Apr;26(2):43-4 - PubMed
  13. Brain Res Bull. 1993;30(3-4):369-71 - PubMed
  14. Nat Biotechnol. 2009 Jan;27(1):59-65 - PubMed
  15. Mol Ther. 2011 Jun;19(6):1058-69 - PubMed
  16. PLoS One. 2012;7(8):e42614 - PubMed
  17. Hum Gene Ther. 2014 Jul;25(7):619-30 - PubMed
  18. PLoS One. 2012;7(3):e32581 - PubMed

Publication Types

Grant support